AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins

被引：10
|
作者：
Evers, Melvin M. [1 ]
Konstantinova, Pavlina [1 ]
机构：
[1] UniQure Biopharma BV, Res, Amsterdam, Netherlands
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2020年 / 20卷 / 10期
关键词：
Huntington disease; huntingtin lowering; HTT; antisense oligonucleotide; ASO; adeno-associated virus; AAV5; microRNA; EMBRYONIC LETHALITY; SUPPRESSION; MODEL; INACTIVATION; IMPROVEMENT; APOPTOSIS; PROTEIN; RNA;
D O I：
10.1080/14712598.2020.1792880
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：1121 / 1124
页数：4
相关论文
共 50 条
  • [41] Gene Therapy in Mouse Models of Huntington Disease
    Southwell, Amber L.
    Patterson, Paul H.
    NEUROSCIENTIST, 2011, 17 (02): : 153 - 162
  • [42] Gene therapy approach for Huntington's disease
    Betuing, Sandrine
    Piguet, Francoise
    Mailly, Philippe
    Hu, Amelie
    Cartier, Nathalie
    Aubourg, Patrick
    Caboche, Jocelyne
    HUMAN GENE THERAPY, 2011, 22 (06) : A21 - A21
  • [43] Efficacy of AAV5-GLA gene therapy in manifest Fabry disease mice
    Liefhebber, Jolanda M. P.
    Brasser, Giso
    Ferraz, Maria J.
    Ottenhoff, Roelof
    Efthymiopoulou, Nikoleta
    Paerels, Lieke
    Pereira, Ines
    Sonea, Andra
    Allart, Leonie
    Schwarz, Lukas K.
    Squeri, Giorgia
    Dobrynin, Greg
    Rodriguez, Rosa Crespo
    Liu, Ying Poi
    Aerts, Johannes M. F. G.
    Montenegro-Miranda, Paula S.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 81 - 82
  • [44] Gene therapy using AAV-Neurturin (CERE-120) in a transgenic mouse model of Huntington's disease
    Ramaswamy, S.
    McBride, J. L.
    Zhou, L.
    Berry-Kravis, E.
    Herzog, C. D.
    Gasmi, M.
    Bartus, R. T.
    Kordower, J. H.
    CELL TRANSPLANTATION, 2007, 16 (03) : 341 - 341
  • [45] AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease
    Connor, B.
    Sun, Y.
    von Hieber, D.
    Tang, S. K.
    Jones, K. S.
    Maucksch, C.
    GENE THERAPY, 2016, 23 (03) : 283 - 295
  • [46] AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease
    B Connor
    Y Sun
    D von Hieber
    S K Tang
    K S Jones
    C Maucksch
    Gene Therapy, 2016, 23 : 283 - 295
  • [47] Gene Therapy for Huntington's Disease: The Future Is in Gene Editing
    Batista, Ana Rita
    HUMAN GENE THERAPY, 2022, 33 (1-2) : 12 - 13
  • [48] AAV-mediated gene therapy of Pompe disease
    Ziegler, RJ
    Bercury, S
    Armentaro, D
    Raben, N
    Cheng, SH
    NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 713 - 713
  • [49] AAV gene therapy for Tay-Sachs disease
    Flotte, Terence R.
    Cataltepe, Oguz
    Puri, Ajit
    Batista, Ana Rita
    Moser, Richard
    McKenna-Yasek, Diane
    Douthwright, Catherine
    Gernoux, Gwladys
    Blackwood, Meghan
    Mueller, Christian
    Tai, Phillip W. L.
    Jiang, Xuntian
    Bateman, Scot
    Spanakis, Spiro G.
    Parzych, Julia
    Keeler, Allison M.
    Abayazeed, Aly
    Rohatgi, Saurabh
    Gibson, Laura
    Finberg, Robert
    Barton, Bruce A.
    Vardar, Zeynep
    Shazeeb, Mohammed Salman
    Gounis, Matthew
    Tifft, Cynthia J.
    Eichler, Florian S.
    Brown, Robert H., Jr.
    Martin, Douglas R.
    Gray-Edwards, Heather L.
    Sena-Esteves, Miguel
    NATURE MEDICINE, 2022, 28 (02) : 251 - +
  • [50] AAV gene therapy for Tay-Sachs disease
    Terence R. Flotte
    Oguz Cataltepe
    Ajit Puri
    Ana Rita Batista
    Richard Moser
    Diane McKenna-Yasek
    Catherine Douthwright
    Gwladys Gernoux
    Meghan Blackwood
    Christian Mueller
    Phillip W. L. Tai
    Xuntian Jiang
    Scot Bateman
    Spiro G. Spanakis
    Julia Parzych
    Allison M. Keeler
    Aly Abayazeed
    Saurabh Rohatgi
    Laura Gibson
    Robert Finberg
    Bruce A. Barton
    Zeynep Vardar
    Mohammed Salman Shazeeb
    Matthew Gounis
    Cynthia J. Tifft
    Florian S. Eichler
    Robert H. Brown
    Douglas R. Martin
    Heather L. Gray-Edwards
    Miguel Sena-Esteves
    Nature Medicine, 2022, 28 : 251 - 259
12345